Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

Gordon Cook; John Ashcroft; Mariana Fernandez; Sarah Henshaw; Zeyad Khalaf; Guy Pratt; Anish Tailor; Neil Rabin

doi:10.3389/fonc.2023.1063144

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

Front Oncol. 2023 Feb 23:13:1063144. doi: 10.3389/fonc.2023.1063144. eCollection 2023.

Authors

Gordon Cook¹, John Ashcroft^{2

3}, Mariana Fernandez⁴, Sarah Henshaw⁵, Zeyad Khalaf⁴, Guy Pratt⁶, Anish Tailor⁷, Neil Rabin⁷

Affiliations

¹ Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
² Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
³ Department of Haematology, Pinderfields General Hospital, Wakefield, United Kingdom.
⁴ Janssen Europe, the Middle East and Africa (EMEA), Beerse, Belgium.
⁵ Department of Haematology, Nottingham University Hospitals, Nottingham, United Kingdom.
⁶ Department of Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
⁷ Department of Haematology, University College London Hospitals, London, United Kingdom.

Abstract

Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early adopter of SC daratumumab and, as such, this report provides consensus recommendations from a group of UK MM experts, with the aim of facilitating the transition from IV to SC daratumumab for other European healthcare providers. The switch from IV to SC daratumumab has been beneficial to patients and healthcare providers, as it simplifies treatment, reduces pressure on hospitals and can improve patients' quality of life.

Keywords: daratumumab; intravenous; multiple myeloma; quality of life; subcutaneous.

Grants and funding

The meeting was facilitated Janssen, who also provided funding for editorial assistance. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Sally Vanden-Hehir, PhD, and Kerry Guest, PhD, of Ashfield MedComms, an Inizio company, and funded by Janssen.